Nautilus Biotechnology (NASDAQ:NAUT) Upgraded at Wall Street Zen

Key Points

• Nautilus Biotechnology has been downgraded to a "sell" rating by Wall Street Zen, with Weiss Ratings also maintaining a "sell (d-)" rating.
• The company's stock is currently trading at $1.22, down 15.9%, with a market capitalization of approximately $154.10 million.
• Ceo Sujal M. Patel recently purchased 83,500 shares at an average cost of $0.68, increasing his ownership stake in the company.

Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) was upgraded by equities research analysts at Wall Street Zen to a "sell" rating in a note issued to investors on Saturday.

Separately, Weiss Ratings reiterated a "sell (d-)" rating on shares of Nautilus Biotechnology in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of "Sell" and an average price target of $2.13.

Nautilus Biotechnology Trading Down 15.9%

NASDAQ:NAUT opened at $1.22 on Friday. Nautilus Biotechnology has a 1 year low of $0.62 and a 1 year high of $2.92. The firm's fifty day simple moving average is $0.83 and its 200 day simple moving average is $0.78. The firm has a market capitalization of $154.10 million, a PE ratio of -2.35 and a beta of 1.48.

Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) last posted its earnings results on Thursday, July 31st. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.02. As a group, analysts anticipate that Nautilus Biotechnology will post -0.57 EPS for the current fiscal year.

Insider Transactions at Nautilus Biotechnology

In related news, CEO Sujal M. Patel purchased 83,500 shares of the firm's stock in a transaction on Monday, September 8th. The shares were bought at an average cost of $0.68 per share, for a total transaction of $56,780.00. Following the transaction, the chief executive officer directly owned 10,341,721 shares of the company's stock, valued at approximately $7,032,370.28. This trade represents a 0.81% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last quarter, insiders have acquired 220,000 shares of company stock valued at $147,635. Company insiders own 41.10% of the company's stock.

Institutional Trading of Nautilus Biotechnology

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Presidio Capital Management LLC grew its position in Nautilus Biotechnology by 246.6% in the 2nd quarter. Presidio Capital Management LLC now owns 34,664 shares of the company's stock worth $25,000 after purchasing an additional 24,664 shares during the last quarter. XTX Topco Ltd acquired a new stake in Nautilus Biotechnology in the 1st quarter worth $31,000. Callan Family Office LLC acquired a new stake in Nautilus Biotechnology in the 2nd quarter worth $35,000. Fayez Sarofim & Co acquired a new stake in Nautilus Biotechnology in the 1st quarter worth $39,000. Finally, Qube Research & Technologies Ltd bought a new position in shares of Nautilus Biotechnology during the 2nd quarter worth about $45,000. 50.71% of the stock is currently owned by institutional investors and hedge funds.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.